UT Health San Antonio is testing an investigational drug that was created to treat COVID-19.
The drug, called remdesivir, is for critically-ill adult patients at University Hospital and is not yet available to the public.
“The study will evolve as we learn which agents work best. If remdesivir is safe and effective, then it will become the standard of care for the trial and new investigational drugs will be studied,” said Dr. Thomas Patterson, professor in the Long School of Medicine and chief of the Division of Infectious Disease.
The treatment study aims to have 440 patients participate worldwide and there are currently 75 testing sites for the drug across the nation.
Patterson is leading the study center that will enroll patients under care at University Hospital. Brooke Army Medical Center is the other San Antonio study site.